3/12
08:21 am
atos
Atossa Therapeutics Presents Clinical Trial Update Highlighting (Z)-Endoxifen Research at the 2026 MDA Clinical & Scientific Conference [Yahoo! Finance]
Medium
Report
Atossa Therapeutics Presents Clinical Trial Update Highlighting (Z)-Endoxifen Research at the 2026 MDA Clinical & Scientific Conference [Yahoo! Finance]
3/12
08:00 am
atos
Atossa Therapeutics Presents Clinical Trial Update Highlighting (Z)-Endoxifen Research at the 2026 MDA Clinical & Scientific Conference
Low
Report
Atossa Therapeutics Presents Clinical Trial Update Highlighting (Z)-Endoxifen Research at the 2026 MDA Clinical & Scientific Conference
2/11
08:30 am
atos
Atossa Therapeutics Issues Letter to Shareholders Highlighting 2025 Accomplishments and 2026 Outlook
High
Report
Atossa Therapeutics Issues Letter to Shareholders Highlighting 2025 Accomplishments and 2026 Outlook
2/5
08:30 am
atos
Atossa Therapeutics Maintains Strong Market Position for (Z)-Endoxifen for Duchenne Muscular Dystrophy as Congress Reauthorizes Priority Review Voucher Program
Medium
Report
Atossa Therapeutics Maintains Strong Market Position for (Z)-Endoxifen for Duchenne Muscular Dystrophy as Congress Reauthorizes Priority Review Voucher Program
1/23
05:06 am
atos
Atossa Genetics (NASDAQ:ATOS) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
Atossa Genetics (NASDAQ:ATOS) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
1/21
09:28 am
atos
Atossa Therapeutics' Founder and CEO Steven Quay, M.D., Ph.D. Named One of The Top 50 Healthcare Technology CEOs of 2025 [Yahoo! Finance]
Low
Report
Atossa Therapeutics' Founder and CEO Steven Quay, M.D., Ph.D. Named One of The Top 50 Healthcare Technology CEOs of 2025 [Yahoo! Finance]
1/21
09:05 am
atos
Atossa Therapeutics' Founder and CEO Steven Quay, M.D., Ph.D. Named One of The Top 50 Healthcare Technology CEOs of 2025
Low
Report
Atossa Therapeutics' Founder and CEO Steven Quay, M.D., Ph.D. Named One of The Top 50 Healthcare Technology CEOs of 2025
1/16
05:28 pm
atos
Atossa Therapeutics Receives FDA Orphan Drug Designation for (Z)-Endoxifen for the Treatment of Duchenne Muscular Dystrophy [Yahoo! Finance]
High
Report
Atossa Therapeutics Receives FDA Orphan Drug Designation for (Z)-Endoxifen for the Treatment of Duchenne Muscular Dystrophy [Yahoo! Finance]
1/16
04:40 pm
atos
Atossa Therapeutics Receives FDA Orphan Drug Designation for (Z)-Endoxifen for the Treatment of Duchenne Muscular Dystrophy
Medium
Report
Atossa Therapeutics Receives FDA Orphan Drug Designation for (Z)-Endoxifen for the Treatment of Duchenne Muscular Dystrophy
1/16
06:47 am
atos
Atossa Therapeutics shares rise after FDA grants orphan drug designation for soft tissue sarcoma [Seeking Alpha]
Low
Report
Atossa Therapeutics shares rise after FDA grants orphan drug designation for soft tissue sarcoma [Seeking Alpha]
1/6
08:37 am
atos
Atossa Therapeutics Receives FDA "Study May Proceed" Letter for (Z)-Endoxifen Investigational New Drug Application for Metastatic Breast Cancer [Yahoo! Finance]
Medium
Report
Atossa Therapeutics Receives FDA "Study May Proceed" Letter for (Z)-Endoxifen Investigational New Drug Application for Metastatic Breast Cancer [Yahoo! Finance]
1/6
08:15 am
atos
Atossa Therapeutics Receives FDA "Study May Proceed" Letter for (Z)-Endoxifen Investigational New Drug Application for Metastatic Breast Cancer
Low
Report
Atossa Therapeutics Receives FDA "Study May Proceed" Letter for (Z)-Endoxifen Investigational New Drug Application for Metastatic Breast Cancer